Daebonglsco.,Ltd Logo

Daebonglsco.,Ltd

Develops raw materials and APIs for the personal care, pharmaceutical, and food industries.

078140 | KO

Overview

Corporate Details

ISIN(s):
KR7078140001
LEI:
Country:
South Korea
Address:
인천광역시 연수구 송도미래로 101 대봉그룹 송도 B&H Plex, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 1980, Daebong LS Co., Ltd. develops, manufactures, and supplies high-quality raw materials for the personal care, pharmaceutical, and food industries. The company specializes in active ingredients for cosmetics and active pharmaceutical ingredients (APIs), leveraging its dedicated research and development centers that focus on convergence technology and natural material applications. Daebong LS provides end-to-end solutions covering the entire business cycle, from raw material sourcing and formulation to final product manufacturing and human application testing. Committed to a mission of enhancing human health and beauty, the company emphasizes innovation, safety, and the development of eco-friendly products.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
Regulatory News Service
[기재정정]본점소재지변경
Korean 8.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-07-29 00:00
Regulatory News Service
본점소재지변경
Korean 5.0 KB
2025-07-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.5 KB
2025-06-30 00:00
Regulatory News Service
[기재정정]신규시설투자등
Korean 12.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.7 MB
2025-04-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.5 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 27.7 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 25.6 KB
2025-03-21 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 525.7 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 14.0 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 152.4 KB
2025-02-17 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 8.9 KB
2025-02-17 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.2 KB
2025-01-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 58.9 KB

Automate Your Workflow. Get a real-time feed of all Daebonglsco.,Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Daebonglsco.,Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Daebonglsco.,Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.